Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

OriGene Completes $16 Million Funding to Build mAb Library

publication date: Mar 22, 2010
OriGene Technologies, Inc., a gene-centric life sciences company based in Maryland, completed a $16 million Series B financing, which it will use to continue building its TrueMAB™ collection of monoclonal antibodies. In February 2009, OriGene purchased the assets of Shenzhen P&A Biotech, a company that provides monoclonal antibodies. OriGene said it would use its new China monoclonal antibody production facility to produce several thousand high quality monoclonal antibodies per year. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital